All articles tagged with #glp 1 drugs
Obesity specialists say GLP-1 weight-loss medications are becoming a wedding trend, with brides like Laura Patnaude losing about 25 pounds to fit into a gown—though experts note caution, as 40 pounds would be risky for the dress and health.
A BuzzFeed News piece gathers Reddit discussions and user anecdotes to explore how GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) could reshape society over 20 years. Predictions span obesity becoming a “disease of poverty,” shifts in beauty standards toward muscle or other traits, and the role of patent expirations and pricing in global access. The article also highlights potential economic and geopolitical effects, factory shifts in the food and insurance industries, and debates over long‑term health impacts and craving dynamics, all illustrating a future where widespread GLP-1 use could alter health, wealth, and culture.
CDC provisional data show the US death rate fell to a record low in 2025 (689.2 per 100,000), with life expectancy likely reaching a new high after hitting 79 years in 2024. The turnaround is driven largely by a sharp decline in overdose deaths (about 70,000 in 2025, down from 114,000 in 2023), plus declines in homicides and Covid deaths, and broad gains in heart disease and cancer mortality. GLP-1 obesity drugs could push life expectancy even higher, but the US still trails peer nations by about 3–4 years and features wide state- and income-related disparities.
Medicare’s one-year Bridge Program now covers GLP-1 weight-loss medications (Foundayo, Wegovy, or Zepbound) for a $50 copay, extending access beyond diabetics to those with BMI 35+ or 27+ with conditions. The move could be a watershed for obesity treatment and trigger broader economic and policy shifts as demand and costs rise.
Medicare is rolling out a temporary Bridge program that will cover GLP-1 weight-loss medications (Wegovy, Zepbound, and Foundayo) for eligible adults at about $50 per month, running through December 2027. To qualify, individuals must be 18+ on Medicare Part D and meet BMI criteria (35+ or 27–34.9 with obesity-related conditions). Studies suggest older adults can lose weight as effectively as younger people on these drugs, but data are still limited and side effects, dehydration, and potential muscle loss mean close medical supervision is essential. Recommendations include staying hydrated, seeking nutritional counseling, prioritizing protein to preserve muscle, engaging in resistance exercise, and keeping goals focused on function rather than a specific weight. The program aims to reduce obesity-related health risks and may improve long-term outcomes, though cost and individual risk must be weighed.
Medicare has started covering certain GLP-1 weight-loss medications with a $50 copay, outlining which drugs are included and the eligibility criteria for beneficiaries. The policy aims to expand access to obesity treatments from manufacturers like Novo Nordisk and Eli Lilly, though coverage may depend on clinical indications and program details.
Louisiana researchers at Pennington Biomedical Center, led by Dr. Eric Ravussin, are studying how GLP-1 weight‑loss drugs affect metabolism and muscle mass, including resting metabolic rate and energy expenditure in a metabolic chamber to understand metabolic adaptation that can slow weight loss, while clinicians emphasize adequate protein and exercise to minimize muscle loss as these therapies evolve.
Beginning Wednesday, Medicare will temporarily cover GLP-1 weight-loss drugs for seniors and certain disabled beneficiaries through an 18-month pilot, with a $50 monthly copay; coverage requires prior authorization and the program’s costs to taxpayers have not been disclosed. Covered drugs include Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy (including the Wegovy pill Foundayo). The move aims to curb obesity-related health risks but raises questions about long-term affordability and access.
Serena Williams returned to competition at Queen’s Club in doubles with Victoria Mboko, signaling a potential Wimbledon run, after revealing she used GLP-1 drugs like tirzepatide and semaglutide to manage weight. The drugs are being monitored by WADA for potential performance enhancement, not banned yet, fueling a broader debate on sport's spirit versus science and how to handle such weight-loss therapies in elite sport.
GLP-1 drugs, originally diabetes meds, are increasingly used for obesity and have helped some patients with weight loss and even relief from joint inflammation, but they carry gastrointestinal side effects and reports of anhedonia; cost and uneven private insurance coverage pose access challenges, prompting doctors to explore dosing adjustments and underscoring that long-term outcomes and broader disease impact require more study.
New observational studies presented at ASCO suggest GLP-1 medications used for diabetes and weight loss (e.g., semaglutide, liraglutide) are associated with a lower incidence of breast cancer and, among those diagnosed, reduced progression and mortality. While promising, the studies cannot prove causation, and researchers are planning randomized trials to test whether GLP-1 drugs can help prevent breast cancer or improve outcomes in high-risk individuals.
An AI-assisted analysis of over 410,000 Reddit posts from six years looked for mentions of GLP-1 drugs (semaglutide or tirzepatide). The researchers found signals suggesting potential side effects in reproductive health (e.g., irregular menstrual cycles) and temperature regulation (chills/hot flashes). They emphasize these are not proven effects or a replacement for clinical trials, but suggest online discussions can reveal underreported symptoms worth investigating as GLP-1 therapies become mainstream. Using OpenAI GPT models to scan Reddit enabled rapid signal detection, with findings published in Nature Health.
A real-world study of 89,718 US patients starting GLP-1 or GLP-1/GIP drugs found that greater weight loss during the first year (BMI drop ≥15%) is tied to substantially lower risks of several obesity-related conditions—osteoarthritis (37%), CKD (30%), sleep apnea (69%), and heart failure (32%)—though the heart failure result wasn’t statistically robust. About half of participants stopped treatment within a year, and the findings imply that health benefits depend on achieving and maintaining weight loss, not just the drugs themselves.
New research suggests GLP-1 drugs like Ozempic—used for obesity and diabetes—may reshape brain networks and influence appetite, mood, cognition and addiction. Early brain scans in teens and young women on GLP-1s showed increased connectivity in the salience network within months, hinting at direct neural effects or indirect changes via gut-brain pathways. Scientists are exploring roles beyond weight loss, including potential impacts on anxiety, compulsive thinking and addiction, while noting that long-term, developmental effects (especially in adolescents) remain unclear. Although some trials hint at neuroprotective signals, a major Alzheimer’s trial with a related drug failed to slow cognitive decline, underscoring that conclusions about brain health from GLP-1s are still uncertain and ongoing.
A Cleveland Clinic retrospective study involving more than 12,000 patients suggests GLP-1 weight‑loss drugs (e.g., semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, pramlintide) may slow progression to advanced disease for several obesity‑related cancers (lung, breast, colorectal, liver), compared with DPP‑4 inhibitors. In four solid tumors, GLP‑1 users showed notably lower progression to stage 4 (up to 50% in non‑small cell lung cancer, 43% breast, 31% colorectal, 38% liver); prostate, pancreatic, and kidney cancers showed non‑significant trends. Tumors with higher GLP‑1 receptor expression also correlated with better survival. The study is not peer‑reviewed and cannot prove causation; randomized trials are needed to confirm mechanisms and effects.